Toolbox
"LAVAL, Quebec--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated announced today that the province of Quebec is now funding INCIVEK™ (telaprevir) tablets for residents living with chronic hepatitis C. The decision comes following a priority evaluation by the Institut National d'Excellence en Santé et en Services Sociaux (INESSS). This decision includes funding for patients who are being treated for the first time as well as those who were treated previously, but did not achieve a sustained virologic response (SVR, or virologic cure), including null responders. (...)"